YouTube Facebook LinkedIn Google+ Twitter Xingrss  

BMS Makes Cuts to Clinical Development/Ops

November 8, 2013 | Bristol-Myers Squibb is making cuts to the clinical development/operations group it acquired when it picked up ZymoGenetics in 2010. The cuts are part of more extended cuts across the company, discontinuing broad based discovery work in hepatitis C, diabetes and neuroscience. Xconomy


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.